LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.

    Tagliamento, Marco / Spagnolo, Francesco / Poggio, Francesca / Soldato, Davide / Conte, Benedetta / Ruelle, Tommaso / Barisione, Emanuela / De Maria, Andrea / Del Mastro, Lucia / Di Maio, Massimo / Lambertini, Matteo

    European journal of clinical investigation

    2020  Volume 50, Issue 9, Page(s) e13315

    Abstract: Background: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer ... an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30 ... of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis.: Materials ...

    Abstract Background: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis.
    Materials and methods: Between 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management.
    Results: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned.
    Conclusions: These results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic.
    MeSH term(s) Adult ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/statistics & numerical data ; Coronavirus Infections/diagnosis ; Coronavirus Infections/epidemiology ; Disease Outbreaks/statistics & numerical data ; Female ; Humans ; Immunocompromised Host ; Immunologic Factors/administration & dosage ; Italy ; Male ; Medical Oncology/methods ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/epidemiology ; Neoplasms/immunology ; Outcome Assessment, Health Care ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/epidemiology ; Risk Assessment ; Surveys and Questionnaires
    Chemical Substances Immunologic Factors
    Keywords covid19
    Language English
    Publishing date 2020-07-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 186196-7
    ISSN 1365-2362 ; 0014-2972 ; 0960-135X
    ISSN (online) 1365-2362
    ISSN 0014-2972 ; 0960-135X
    DOI 10.1111/eci.13315
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Italian survey on managing immune checkpoint inhibitors in oncology during COVID19 outbreak

    Tagliamento, Marco / Spagnolo, Francesco / Poggio, Francesca / Soldato, Davide / Conte, Benedetta / Ruelle, Tommaso / Barisione, Emanuela / De Maria, Andrea / Del Mastro, Lucia / Di Maio, Massimo / Lambertini, Matteo

    European Journal of Clinical Investigation

    2020  Volume 50, Issue 9

    Keywords Clinical Biochemistry ; Biochemistry ; General Medicine ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 186196-7
    ISSN 1365-2362 ; 0014-2972 ; 0960-135X
    ISSN (online) 1365-2362
    ISSN 0014-2972 ; 0960-135X
    DOI 10.1111/eci.13315
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak

    Tagliamento, Marco / Spagnolo, Francesco / Poggio, Francesca / Soldato, Davide / Conte, Benedetta / Ruelle, Tommaso / Barisione, Emanuela / De Maria, Andrea / Del Mastro, Lucia / Di Maio, Massimo / Lambertini, Matteo

    Eur J Clin Invest

    Abstract: BACKGROUND: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer ... an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30 ... of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. MATERIALS ...

    Abstract BACKGROUND: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. MATERIALS AND METHODS: Between 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management. RESULTS: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned. CONCLUSIONS: These results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #597270
    Database COVID19

    Kategorien

  4. Article ; Online: Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak

    Tagliamento, M. / Spagnolo, F. / Poggio, F. / Soldato, D. / Conte, B. / Ruelle, T. / Barisione, E. / De Maria, A. / Del Mastro, L. / Di Maio, M. / Lambertini, M.

    2020  

    Abstract: Background: During COVID-19 outbreak, oncological care has been reorganized. Cancer patients have ... of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest ... of an interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. Materials and Methods ...

    Abstract Background: During COVID-19 outbreak, oncological care has been reorganized. Cancer patients have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of an interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. Materials and Methods: Between May 6 and 16, 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed to explore the perception about SARS-CoV-2 related risks in cancer patients receiving ICIs, and the attitudes towards their management. Results: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labeled dose of each ICI (55.8%) and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnea and cough as SARS-CoV-2 infected until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned. Conclusions: These results highlight the confusion around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic.
    Keywords COVID-19 ; SARS-CoV-2 ; cancer ; immune checkpoint inhibitors ; immunotherapy ; covid19
    Subject code 616
    Language English
    Publisher Blackwell Publishing Ltd
    Publishing country it
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.

    Ottaviano, Margaret / Curvietto, Marcello / Rescigno, Pasquale / Tortora, Marianna / Palmieri, Giovannella / Giannarelli, Diana / Aieta, Michele / Assalone, Pasquale / Attademo, Laura / Avallone, Antonio / Bloise, Francesco / Bosso, Davide / Borzillo, Valentina / Buono, Giuseppe / Calderoni, Giuseppe / Caputo, Francesca / Cartenì, Giacomo / Cavallero, Diletta / Cavo, Alessia /
    Ciardiello, Fortunato / Conca, Raffaele / Conteduca, Vincenza / De Falco, Stefano / De Felice, Marco / De Laurentiis, Michelino / De Placido, Pietro / De Placido, Sabino / De Santo, Irene / De Stefano, Alfonso / Della Corte, Carminia Maria / Di Franco, Rossella / Di Lauro, Vincenzo / Fabbrocini, Antonietta / Federico, Piera / Festino, Lucia / Giordano, Pasqualina / Giuliano, Mario / Gridelli, Cesare / Grimaldi, Antonio Maria / Lia, Michela / Marretta, Antonella Lucia / Massa, Valentina / Mennitto, Alessia / Merler, Sara / Merz, Valeria / Messina, Carlo / Messina, Marco / Milano, Monica / Minisini, Alessandro Marco / Montesarchio, Vincenzo / Morabito, Alessandro / Morgillo, Floriana / Mucci, Brigitta / Nappi, Lucia / Napolitano, Fabiana / Paciolla, Immacolata / Pagliuca, Martina / Palmieri, Giuseppe / Parola, Sara / Pepe, Stefano / Petrillo, Angelica / Piantedosi, Francovito / Piccin, Luisa / Picozzi, Fernanda / Pietroluongo, Erica / Pignata, Sandro / Prati, Veronica / Riccio, Vittorio / Rosanova, Mario / Rossi, Alice / Russo, Anna / Salati, Massimiliano / Santabarbara, Giuseppe / Sbrana, Andrea / Simeone, Ester / Silvestri, Antonia / Spada, Massimiliano / Tarantino, Paolo / Taveggia, Paola / Tomei, Federica / Vincenzo, Tortora / Trapani, Dario / Trojanello, Claudia / Vanella, Vito / Vari, Sabrina / Ventriglia, Jole / Vitale, Maria Grazia / Vitiello, Fabiana / Vivaldi, Caterina / von Arx, Claudia / Zacchi, Francesca / Zampiva, Ilaria / Zivi, Andrea / Daniele, Bruno / Ascierto, Paolo Antonio

    Journal for immunotherapy of cancer

    2020  Volume 8, Issue 2

    Abstract: ... This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique ... worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune ... of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus ...

    Abstract Background: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.
    Methods: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ
    Results: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.
    Conclusion: Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
    MeSH term(s) Adult ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Coronavirus Infections/epidemiology ; Coronavirus Infections/immunology ; Coronavirus Infections/prevention & control ; Coronavirus Infections/transmission ; Drug Prescriptions/statistics & numerical data ; Female ; Geography ; Humans ; Infection Control/standards ; Italy/epidemiology ; Male ; Medical Oncology/standards ; Medical Oncology/statistics & numerical data ; Neoplasms/drug therapy ; Neoplasms/immunology ; Oncologists/statistics & numerical data ; Pandemics/prevention & control ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/immunology ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/transmission ; Practice Patterns, Physicians'/standards ; Practice Patterns, Physicians'/statistics & numerical data ; Prevalence ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; SARS-CoV-2 ; Surveys and Questionnaires/statistics & numerical data ; Time-to-Treatment
    Chemical Substances Antineoplastic Agents, Immunological ; B7-H1 Antigen ; CD274 protein, human ; CTLA-4 Antigen ; CTLA4 protein, human ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor
    Keywords covid19
    Language English
    Publishing date 2020-09-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-001154
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Impact of COVID-19 outbreak on cancer immunotherapy in Italy

    Ottaviano, Margaret / Curvietto, Marcello / Rescigno, Pasquale / Tortora, Marianna / Palmieri, Giovannella / Giannarelli, Diana / Aieta, Michele / Assalone, Pasquale / Attademo, Laura / Avallone, Antonio / Bloise, Francesco / Bosso, Davide / Borzillo, Valentina / Buono, Giuseppe / Calderoni, Giuseppe / Caputo, Francesca / Cartenì, Giacomo / Cavallero, Diletta / Cavo, Alessia /
    Ciardiello, Fortunato / Conca, Raffaele / Conteduca, Vincenza / De Falco, Stefano / De Felice, Marco / De Laurentiis, Michelino / De Placido, Pietro / De Placido, Sabino / De Santo, Irene / De Stefano, Alfonso / Della Corte, Carminia Maria / Di Franco, Rossella / Di Lauro, Vincenzo / Fabbrocini, Antonietta / Federico, Piera / Festino, Lucia / Giordano, Pasqualina / Giuliano, Mario / Gridelli, Cesare / Grimaldi, Antonio Maria / Lia, Michela / Marretta, Antonella Lucia / Massa, Valentina / Mennitto, Alessia / Merler, Sara / Merz, Valeria / Messina, Carlo / Messina, Marco / Milano, Monica / Minisini, Alessandro Marco / Montesarchio, Vincenzo / Morabito, Alessandro / Morgillo, Floriana / Mucci, Brigitta / Nappi, Lucia / Napolitano, Fabiana / Paciolla, Immacolata / Pagliuca, Martina / Palmieri, Giuseppe / Parola, Sara / Pepe, Stefano / Petrillo, Angelica / Piantedosi, Francovito / Piccin, Luisa / Picozzi, Fernanda / Pietroluongo, Erica / Pignata, Sandro / Prati, Veronica / Riccio, Vittorio / Rosanova, Mario / Rossi, Alice / Russo, Anna / Salati, Massimiliano / Santabarbara, Giuseppe / Sbrana, Andrea / Simeone, Ester / Silvestri, Antonia / Spada, Massimiliano / Tarantino, Paolo / Taveggia, Paola / Tomei, Federica / Vincenzo, Tortora / Trapani, Dario / Trojanello, Claudia / Vanella, Vito / Vari, Sabrina / Ventriglia, Jole / Vitale, Maria Grazia / Vitiello, Fabiana / Vivaldi, Caterina / von Arx, Claudia / Zacchi, Francesca / Zampiva, Ilaria / Zivi, Andrea / Daniele, Bruno / Ascierto, Paolo Antonio

    a survey of young oncologists

    2020  

    Abstract: ... regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint ... with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania ... The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data ...

    Abstract The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.
    Keywords antineoplastic protocols ; healthcare economics and organizations ; immunotherapy ; lung neoplasms ; melanoma ; covid19
    Language English
    Publishing country it
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Impact of COVID-19 outbreak on cancer immunotherapy in Italy

    Ottaviano, Margaret / Curvietto, Marcello / Rescigno, Pasquale / Tortora, Marianna / Palmieri, Giovannella / Giannarelli, Diana / Aieta, Michele / Assalone, Pasquale / Attademo, Laura / Avallone, Antonio / Bloise, Francesco / Bosso, Davide / Borzillo, Valentina / Buono, Giuseppe / Calderoni, Giuseppe / Caputo, Francesca / Cartenì, Giacomo / Cavallero, Diletta / Cavo, Alessia /
    Ciardiello, Fortunato / Conca, Raffaele / Conteduca, Vincenza / De Falco, Stefano / De Felice, Marco / De Laurentiis, Michelino / De Placido, Pietro / De Placido, Sabino / De Santo, Irene / De Stefano, Alfonso / Della Corte, Carminia Maria / Di Franco, Rossella / Di Lauro, Vincenzo / Fabbrocini, Antonietta / Federico, Piera / Festino, Lucia / Giordano, Pasqualina / Giuliano, Mario / Gridelli, Cesare / Grimaldi, Antonio Maria / Lia, Michela / Marretta, Antonella Lucia / Massa, Valentina / Mennitto, Alessia / Merler, Sara / Merz, Valeria / Messina, Carlo / Messina, Marco / Milano, Monica / Minisini, Alessandro Marco / Montesarchio, Vincenzo / Morabito, Alessandro / Morgillo, Floriana / Mucci, Brigitta / Nappi, Lucia / Napolitano, Fabiana / Paciolla, Immacolata / Pagliuca, Martina / Palmieri, Giuseppe / Parola, Sara / Pepe, Stefano / Petrillo, Angelica / Piantedosi, Francovito / Piccin, Luisa / Picozzi, Fernanda / Pietroluongo, Erica / Pignata, Sandro / Prati, Veronica / Riccio, Vittorio / Rosanova, Mario / Rossi, Alice / Russo, Anna / Salati, Massimiliano / Santabarbara, Giuseppe / Sbrana, Andrea / Simeone, Ester / Silvestri, Antonia / Spada, Massimiliano / Tarantino, Paolo / Taveggia, Paola / Tomei, Federica / Vincenzo, Tortora / Trapani, Dario / Trojanello, Claudia / Vanella, Vito / Vari, Sabrina / Ventriglia, Jole / Vitale, Maria Grazia / Vitiello, Fabiana / Vivaldi, Caterina / von Arx, Claudia / Zacchi, Francesca / Zampiva, Ilaria / Zivi, Andrea / Daniele, Bruno / Ascierto, Paolo Antonio

    Journal for ImmunoTherapy of Cancer

    a survey of young oncologists

    2020  Volume 8, Issue 2, Page(s) e001154

    Abstract: ... worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune ... of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus ... checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management ...

    Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
    Keywords Immunology ; Immunology and Allergy ; Molecular Medicine ; Cancer Research ; Oncology ; Pharmacology ; covid19
    Language English
    Publisher BMJ
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 2719863-7
    ISSN 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-001154
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

    Ottaviano, Margaret / Curvietto, Marcello / Rescigno, Pasquale / Tortora, Marianna / Palmieri, Giovannella / Giannarelli, Diana / Aieta, Michele / Assalone, Pasquale / Attademo, Laura / Avallone, Antonio / Bloise, Francesco / Bosso, Davide / Borzillo, Valentina / Buono, Giuseppe / Calderoni, Giuseppe / Caputo, Francesca / Cartenì, Giacomo / Cavallero, Diletta / Cavo, Alessia /
    Ciardiello, Fortunato / Conca, Raffaele / Conteduca, Vincenza / De Falco, Stefano / De Felice, Marco / De Laurentiis, Michelino / De Placido, Pietro / De Placido, Sabino / De Santo, Irene / De Stefano, Alfonso / Della Corte, Carminia Maria / Di Franco, Rossella / Di Lauro, Vincenzo / Fabbrocini, Antonietta / Federico, Piera / Festino, Lucia / Giordano, Pasqualina / Giuliano, Mario / Gridelli, Cesare / Grimaldi, Antonio Maria / Lia, Michela / Marretta, Antonella Lucia / Massa, Valentina / Mennitto, Alessia / Merler, Sara / Merz, Valeria / Messina, Carlo / Messina, Marco / Milano, Monica / Minisini, Alessandro Marco / Montesarchio, Vincenzo

    J. immunotherap. cancer

    Abstract: ... worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune ... of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus ... checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management ...

    Abstract BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #873574
    Database COVID19

    Kategorien

To top